Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

UNKNOWN 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 40HER2 Positive Metastatic Breast Cancer 4Breast Diseases 4Brain Neoplasms 4Carcinoma, Non-Small-Cell Lung 3Stomach Neoplasms 2HER2-positive Breast Cancer 2Colorectal Neoplasms 2Advanced Breast Cancer 2Triple Negative Breast Neoplasms 1Solid Tumor 1Salivary Gland Neoplasms 1Pathologic Complete Response 1Neoplasm Metastasis 1Neoadjuvant Treatment for HER2-positive, ER-positive Breast Cancer 1HER2-positive Metastatic Breast Cancer 1HER2+ Early or Locally Advanced Breast Cancer 1HER2+ Breast Cancer 1HER2 Positive Gastric Cancer 1HER2 Positive Breast Cancer 1HER-2 Positive Colorectal Cancer 1Estrogen Receptor-positive Breast Cancer 1Digestive System Neoplasms 1Carcinoma, Transitional Cell 1

Interventions

toripalimab 4pembrolizumab 4Gemcitabine 4tislelizumab 2durvalumab 2Nivolumab 2Cisplatin 2Carboplatin 2AZD4547 2tipifarnib 1tesetaxel 1sapanisertib 1regorafenib 1pyrotinib 1nintedanib 1famitinib 1disitamab vedotin 1camrelizumab 1bintrafusp alfa protein, human 1atezolizumab 1anlotinib 1aldesleukin 1advexin 1Vitamin B 12 1Trastuzumab 1Taxes 1Surgical Procedures, Operative 1Saline Solution 1Resistance Training 1Pemetrexed 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Carcinoma, Transitional Cell × pyrotinib × Clear all
NCT05318339 2022-04-08

A Study of Trastuzumab and Pyrotinib in HER2 Positive Locally Advanced or Metastatic Urothelial Carcinoma

ChineseAMS

Phase 2 Unknown
30 enrolled
Genitourinary

Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡